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There is evidence that individuals with posttraumatic stress disorder (PTSD) may smoke in part to regulate negative aﬀect. This
pilot fMRI study examined the eﬀects of nicotine on emotional information processing in smokers with and without PTSD. Across
groups,nicotineincreasedbrainactivationinresponsetofearful/angryfaces(comparedtoneutralfaces)inventralcaudate.Patchx
Group interactions were observed in brain regions involved in emotional and facial feature processing. These preliminary ﬁndings
suggest that nicotine diﬀerentially modulates negative information processing in PTSD and non-PTSD smokers.
1.Introduction
Posttraumatic stress disorder (PTSD) is associated with
elevated rates of cigarette smoking (40%–63%) compared
with population norms (20%–30%) [1–3]. Moreover, smok-
ers with PTSD are signiﬁcantly more likely to be “heavy”
smokers (i.e., smoke >25 cigarettes/day) [4] and take larger
puﬀs[ 5]. In naturalistic studies, PTSD smokers are more
likelytoreportnegativeaﬀective(NA)statesasanantecedent
to smoking [6] and also report signiﬁcant reductions in NA
following smoking [7].
A hallmark phenotype of individuals with PTSD is in-
creased psychophysiological responsivity and NA to idio-
pathic trauma-related stimuli [8]. Furthermore, individuals
with PTSD exhibit aberrant responding to nonspeciﬁc,
negative emotional stimuli [9]. For instance, individuals
with PTSD exhibit biased attention to negative emotional
information [10, 11]. Moreover, compared to non-PTSD
trauma survivors, PTSD survivors have increased electrocor-
ticalresponsestosadfaces[12].Ithasbeenproposed[13,14]
thatdysregulatedemotionalinformationprocessinginPTSD
is due to hyperresponsiveness of the amygdala—a region
subserving negative emotional information processes [15]—
andalsohyporesponsivenessofmedialprefrontalcortices—a
region involved in cognitive control of emotional responses
[16].SupportforthishypothesiscomesfromfMRIstudiesof
PTSD patients showing increased reactivity to fearful faces in
amygdala as compared to controls [17, 18] coincident with
decreased reactivity in medial prefrontal regions [18].
Laboratory studies show that smoking and nicotine
reduces distraction caused by negative stimuli [19]a n d
electrocortical responses [20] to these stimuli among smok-
ers. Moreover, neuroimaging studies show that nicotine
acts on limbic (e.g., amygdala) and prefrontal brain areas
that subserve emotional information processing [21–23].
Despite evidence regarding smoking/PTSD interactions, no
neuroimaging studies to date have evaluated the neurobio-
logical basis of nicotine and/or smoking eﬀects on emotional
informationprocessingamongindividualswithPTSD.Thus,
we conducted a preliminary study aimed at evaluating this
question. Smokers with and without a PTSD diagnosis
underwent fMRI scanning 2 hrs after application of a 21mg
transdermal nicotine or placebo patch. During scanning
participants viewed emotional or neutral face stimuli. We2 Advances in Pharmacological Sciences
Table 1: Participant demographicsab.
Sub. Age Sex FTND Cigs/day Yrs smoked BDI PTSD
(CAPS) Psychiatric history Trauma event Drug dep. hx
P-1 27 F 5 10 9 1 Yes MDD, OCD,
Adjustment disorder Witness to assault Alcohol
P-2 41 F 3 20 25 11 Yes None Death of daughter None
P-3 28 F 8 50 11 24 Yes Agoraphobia, speciﬁc
phobia (heights), MDD
Children removed
by social services None
P-4 31 F 6 15 15 9 Yes MDD Child sexual abuse
C-1 68 F 5 60 49 2 No MDD Death of husband Alcohol
C-2 27 M 4 15 8 0 No None Hurricane None
C-3 28 F 3 13 12 1 No None None None
C-4 43 F 10 39 31 10 No Subthreshold OCD Death of friend None
aPTSD group subjects are denoted as de-identiﬁed subject numbers P-1 through P-4.
bControl group subjects are denoted as de-identiﬁed subject numbers C-1 through C-4.
hypothesized that nicotine and PTSD, both separately and
in combination, would have eﬀects on brain activation,
speciﬁcally in regions underlying emotional processes.
2.MaterialsandMethods
2.1. Subjects and Stimuli. Participants (n = 11) were adult
smokers with and without PTSD recruited from community
and clinic sources. Eligibility requirements included being
between the ages of 18–75, smoking ≥10 cigarettes per day
over the past year, abstinence from nicotine delivery other
than cigarettes, having 20/20 corrected vision, native English
speaking, free of any neurological history, or major medical
problems, passing a urine drug screen and pregnancy test if
female and not meeting DSM-IV criteria for current drug
or alcohol abuse/dependence (except nicotine). Participants
read and signed an Institutional Review Board approved
informed consent form and were paid $250 upon study
completion. Eleven participants completed all aspects of
the study. Data from 3 participants were excluded due to
computer hardware diﬃculty (n = 2) and data-related
problems (n = 1).
2.2. Procedure. Participants completed three sessions—one
screening/diagnostic and two scanning sessions. PTSD diag-
nosis was based on the Clinician Administered PTSD Scale
[24]. Other psychiatric disorders were diagnosed based on
theStructuredClinicalInterviewforDSM-IVdiagnosis[25].
Current alcohol and drug abuse/dependence diagnoses were
determined by a 3-month time frame; current diagnoses
for major depressive episode and anxiety disorders were
determined by a 1-month time frame. Two trained raters
(kappa for diagnoses = .97) conducted the interviews under
the supervision of a licensed clinical psychologist (JCB). The
Beck Depression Inventory (BDI), the Fagerstr¨ om test for
Nicotine Dependence (FTND), and a smoking history form
were administered (see Table 1).
On each experimental day, participants were adminis-
tered either a transdermal nicotine (21mg NicoDerm) or
placebopatch.Placebopatches(resemblingnicotinepatches)
were manufactured by 1–800-PATCHES. Participants were
instructed to smoke as usual up to patch administration.
The patch was placed on the lower upper arm to avoid
complications during scanning. In the 2 hrs following patch
application, participants maintained smoking abstinence
and were monitored by study personnel. After 2 hours,
participants entered the MRI suite, were placed in the
scanner, and then performed an experimental task during
fMRI scanning. Patch order was randomly assigned and
counterbalanced across participants.
2.3. Experimental Task. The experimental task was a mod-
iﬁed version of a face viewing task previously shown to
increase activation in brain regions underlying emotion
processing [26]; see Figure 1. In brief, neutral and negative
(angry and fearful) faces [27] were presented in a dynamic
(i.e., morphed) fashion. The morphing caused them to
appear to change from neutral to negative in the same actor
(emotion morph) or from one neutral identity to another
neutral identity (identity morph). Trials were separated by
a ﬁxation cross. Participants used a response box to indicate
whethereachfacedepictedanemotionoranidentitymorph.
Stimuli were presented in a pseudorandom event-related
design. The intertrial interval varied between 12 and 15s (M
=13.5s).Eachsessionwasdividedintoeight,8min24sruns.
Run order was counterbalanced across participants.
2.4. Scanning Procedures. MR images were acquired on a
1.5T General Electric Signa NVi scanner (Milwaukee, WI,
USA) equipped with 41mT/m gradients. The participant’s
head was immobilized using a cushion and tape. The
a n t e r i o ra n dp o s t e r i o rc o m m i s s u r e sw e r ei d e n t i ﬁ e di nt h e
midsagittal slice of a localizer series. A high-resolution
T1-weight anatomical image was then acquired (124 con-
tiguous slices, repetition time, TR = 8.2s, TE = 3.3ms,
FOV = 24cm, matrix = 2562, slice thickness = 1.5mm).
Functional images were collected during the task with an
inverse spiral pulse sequence sensitive to blood-oxygenation-
level-dependent (BOLD) contrast (30 slices, TR = 1.5s,Advances in Pharmacological Sciences 3
Table 2: Brain areas where signiﬁcant main eﬀects of group were observed.
Side Brain area BA Cluster size (mm3)
MNI coordinates
xyz T max
PTSD > control
L Fusiform gyrus 37 744 −42 −54 −20 6.33
19 −38 −68 −18 6.25
R Putamen 200 32 −10 −85 . 4 8
R Amygdala 26 −6 −12 4.75
R Caudate 208 10 −62 2 5 . 2 1
12 −21 4 3 . 8 6
L Caudate 280 −84 8 4 . 8 5
R Angular gyrus 19 152 40 −78 44 4.73
L Thalamus 280 −18 −20 14 4.6
−12 −26 12 4.45
L Superior frontal gyrus 8 104 −22 38 48 4.53
R Inferior frontal gyrus 9 96 60 20 26 4.24
R Thalamus 104 16 −41 2 4 . 1 2
Control > PTSD
No signiﬁcant areas of activation
Experimental paradigm
Emotional morph
trial
12 s
Identity morph
trial
1.5 s
(AVI 45 frames/30 frames/s)
+
+
Figure 1: fMRI task paradigm.
TE = 10ms, FOV = 24cm, matrix = 642,ﬂ i pa n g l e= 81◦,
slice thickness = 3.8mm, in-plane resolution = 3.75mm2).
2.5. Data Analysis. The fMRI data analysis utilized a voxel-
based approach implemented in SPM5 (Wellcome Trust
Centre for Neuroimaging, London, UK). Preprocessing steps
included (1) slice-time correction, (2) realignment using
rigid body translation and rotation, (3) normalization into a
standard stereotaxic space (Montreal Neurological Institute)
with an isotropic 2mm3 voxel size, and (4) smoothing with
an 8mm Gaussian ﬁlter.
For each participant on each session, statistical para-
metric maps were derived by applying linear contrasts to
the parameter estimates for the event of interest (emotional
morph > identity morph), resulting in a t-statistic for every
voxel. These contrasts were then passed onto the second
level for random-eﬀects analyses. Statistical contrasts were
set up to calculate signal diﬀerences between patch condition
(nicotine versus placebo), group (PTSD versus control), and
the 2-way interaction between patch and group. A gray
matter mask was applied to statistical parametric maps, and
results were thresholded at P<0.001, uncorrected, with a
spatial extent of ten contiguous voxels.
3. Results
3.1. Participant Demographics. Participants were adult
smokers with (n = 4) and without PTSD (n = 4). See Table 1
for smoking history and demographic information. Groups
were matched on age (sample M = 36.6, SD = 14.2), average
number of years smoked (M = 20, SD = 14.3), cigarettes per
day (M = 19.2, SD = 6.8), and nicotine dependence (FTND
score M = 5.5; SD = 2.4).4 Advances in Pharmacological Sciences
Placebo > nicotine
t = 3.79 t = 6
z = 12mm
Nicotine > placebo
y = 9mm
P ≤ 0.001, 10 voxels
Figure 2: fMRI contrast of the main eﬀects of patch type. Across
groups, activation (emotion morph > identity morph) was greater
for nicotine versus placebo patch in left caudate (x =− 10, y = 14,
z =− 6), whereas greater activation was observed in left inferior
frontal gyrus (IFG) (x =− 42, y = 8, z = 8) and right middle
occipital gyrus (MOG) (x = 32, y =− 88, z = 4) for placebo versus
nicotine patch.
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Figure 3: Model parameter estimates of the main eﬀect of patch
type on task-related left caudate (x =− 10, y = 14, z =− 6) BOLD
response.
3.2. fMRI Activations. Patch eﬀects Across groups, nicotine
patch compared to placebo resulted in increased activation
in left ventral caudate (Figures 2 and 3). As represented
in Figure 2, signiﬁcant activations for placebo relative to
nicotine patch were observed in right middle occipital gyrus
(BA 19) and left inferior frontal gyrus (BA 44).
Group Eﬀects. Acrosspatchconditions,activationwassignif-
icantly greater in the PTSD as compared to non-PTSD group
in striatum, amygdala, and frontal, parietal, and occipital
cortices (see Table 2). No activations were greater in the non-
PTSD relative to PTSD group.
Patch x Group Interaction. As represented in Figure 4, patch
x group interactions were observed in right superior frontal
gyrus (SFG) (Figure 5) and left middle temporal gyrus
(MTG). In SFG, activation was greatest in the PTSD group
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Figure 4: fMRI contrast of the patch x group interactions.
Signiﬁcant patch x group interactions were observed in right
superior frontal gyrus (SFG) (x = 24, y = 22, z = 60) and left
middle temporal gyrus (MTG) (x =− 48, y =− 10, z =− 24).
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Figure 5: Model parameter estimates of the group x patch
interaction on task-related right superior frontal gyrus (SFG) (x =
24, y = 22, z = 60) BOLD response.
than that in the placebo condition. In MTG, activation was
greater in the PTSD group in the nicotine relative to placebo
condition; the opposite pattern was observed in the non-
PTSD group.
4. Discussion
This preliminary study is the ﬁrst to systematically assess the
eﬀects of nicotine on neural correlates of emotional infor-
mation processing in a PTSD sample. As in previous studies
[17, 18], PTSD was associated with larger brain responses to
emotional face stimuli in amygdala and prefrontal regions.Advances in Pharmacological Sciences 5
In evaluating the eﬀects of nicotine, we observed patch
x group interactions in several brain areas which suggest
nicotine might modulate emotional information processing
via diﬀerent neural mechanisms in smokers with and with-
out PTSD. The observed patch x group interaction in SFG
suggested greater reactivity to emotional cues in this region
when smokers with PTSD were in a nicotine-deprived state.
The SFG plays an important role in emotion, memory, and
motivational processes. As compared to controls, individuals
with PTSD have been shown to exhibit increased activation
in SFG upon recall of neutral information that was encoded
in an emotional context [28]. A patch x group interaction
was also observed in MTG—a region previously shown to
be selectively active in response to nonaﬀective components
of face stimuli (e.g., perception and familiarity; [29]). This
area was more reactive to emotional face cues in smokers
with PTSD when receiving nicotine. Collectively, these
ﬁndings suggest that nicotine (and nicotine deprivation)
may modulate reactivity to the nonaﬀective and aﬀective
components of face stimuli in smokers with PTSD.
In addition to the above interactions, we observed a
main eﬀect of nicotine in which activation to emotional
face stimuli was greater in left ventral caudate following
nicotine patch administration. The ventral caudate is part
of the ventral striatum—a brain region that mediates
reward processes [30]. Nicotine stimulates the release of
dopamine in the ventral striatum in both animals [31]a n d
in human smokers [32]. Likewise, nicotine abstinence results
in decreased ventral striatal dopamine functioning [33].
Thus, our novel ﬁndings of nicotine-induced increases in
reactivity to emotional stimuli in the striatum may be due
to increased dopamine transmission in this region brought
on by nicotine administration (or decreases in dopamine
neurotransmission in the absence of nicotine).
The present study has limitations including a small
sample size and a relatively heterogeneous sample with
respect to age, psychiatric comorbidity, and smoking history.
We manipulated nicotine in the context of brief abstinence
so it remains unknown what eﬀect a longer abstinence
period would have on emotional information processing.
Additional work with larger samples and under other
clinically relevant conditions is needed.
5. Conclusion
The present preliminary study provides novel information
regarding the eﬀects of nicotine on emotional information
processinginsmokerswithandwithoutPTSD.Smokerswith
PTSD report greater NA immediately prior to smoking [34]
and greater decreases in NA following smoking [35], and
these ﬁndings are consistent with the observed patterns of
brain activation in the current study. Thus, our ﬁndings
provide a neurobiological basis that helps explain why
individuals with PTSD are at greater risk of smoking and
also experience greater diﬃculty quitting. The present study
is not without its limitations. Our sample size was small
and was predominately represented by female smokers.
Moreover, among the female participants, we did not obtain
information regarding menstrual cycle phase in relation to
the timing of each of their experimental sessions which
may have added some variance to the results. Future work
will examine the eﬀects of nicotine and smoking in larger
samples of smokers with PTSD, control for sex diﬀerences,
and among females control for time in menstrual cycle,
and relate these ﬁndings to smoking-related outcomes (e.g.,
smoking cessation success/failure).
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